Home Premium Research

Premium Research

Latest

Inside The FDA: Why Cempra Inc (NASDAQ:CEMP) Solithromycin Yes Vote Isn’t The Whole Story

Market Exclusive Intelligence - November 16, 2016

“Inside the FDA” Biotech Research On Egalet Corp. (NASDAQ:EGLT) Arymo Decision

Inside the FDA: Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s Psoriasis Drug, Brodalumab.

Inside the FDA: Insys Therapeutics Inc. (NASDAQ:INSY) and Sublingual Naloxone

Inside The FDA: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) and its Bladder Cancer Treatment, Apaziquone

Inside the FDA: Why The Pfizer, Inc. (NYSE:PFE) Boxed Warning On...

David Rich - September 16, 2016 0

Inside The FDA: Eli Lilly and Co (NYSE:LLY) Jardiance Aims at...

David Rich - September 9, 2016 0

As Old Bestsellers Plateau, a Look at 4 Next Generation Diabetes...

David Rich - June 27, 2016 1

The Top Four Diabetes Best Sellers and One Oral Insulin Pill...

David Rich - June 22, 2016 0

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

November 18, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024

November 10, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024

October 27, 2024

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

ABOUT US

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.